handshake-1
miodrag ignjatovic / iStockphoto.com
12 February 2018Asia-Pacific

Allergan to buy Australian tissue repair company for $95m

Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Americas
6 March 2018   Mylan has revealed plans to develop and commercialise a proposed biosimilar to Botox.
Americas
18 September 2018   Allergan has revealed plans to buy Bonti, a biotechnology company focused on medical aesthetics, for $195 million.

More on this story

Americas
6 March 2018   Mylan has revealed plans to develop and commercialise a proposed biosimilar to Botox.
Americas
18 September 2018   Allergan has revealed plans to buy Bonti, a biotechnology company focused on medical aesthetics, for $195 million.
Americas
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.

More on this story

Americas
6 March 2018   Mylan has revealed plans to develop and commercialise a proposed biosimilar to Botox.
Americas
18 September 2018   Allergan has revealed plans to buy Bonti, a biotechnology company focused on medical aesthetics, for $195 million.
Americas
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.